Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 265 of 265Qilu Hospital of Shandong University
The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019,which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lunginjury (ALI) and acute respiratory distress syndrome (ARDS) in patients with severeCOVID-19. Pulmonary edema is the key detrimental feature of ALI/ARDS. Autopsy of patientsdied from COVID-19 reported that, pulmonary mucus exudation was more severe and obviousthan SARS infection. Pulmonary CT scanning and pathological findings also suggest thatpulmonary edema caused by inflammatory exudation is a distinguished feature of COVID-19.Vascular endothelial growth factor (VEGF), also known as vascular permeability factor(VPF), is known as the most potent factor to increase vascular permeability, with theinduction effect 50,000 times stronger than histamine. Bevacizumab is an anti-VEGFrecombinant humanized monoclonal antibody, which has been used in anti-tumor treatmentsince 2004, with considerable reliability and clinical safety. This trial will providehigh level evidence to answer whether bevacizumab is efficacy and safe medication forpatients with severe COVID-19.
Massachusetts General Hospital
Thousands of healthcare workers have been infected with SARS-CoV-2 and contractedCOVID-19 despite their best efforts to prevent contamination. No proven vaccine isavailable to protect healthcare workers against SARS-CoV-2.This study will enroll 470 healthcare professionals dedicated to care for patients withproven SARS-CoV-2 infection. Subjects will be randomized either in the observational(control) group or in the inhaled nitric oxide group. All personnel will observe measureson strict precaution in accordance with WHO and the CDC regulations.
University College, London
Modelling repurposed from pandemic influenza is currently informing all strategies forSARS-CoV-2 and the disease COVID-19. A customized disease specific understanding will beimportant to understand subsequent disease waves, vaccine development and therapeutics.For this reason, ISARIC (the International Severe Acute Respiratory and EmergingInfection Consortium) was set up in advance. This focuses on hospitalised andconvalescent serum samples to understand severe illness and associated immune response.However, many subjects are seroconverting with mild or even subclinical disease.Information is needed about subclinical infection, the significance of baseline immunestatus and the earliest immune changes that may occur in mild disease to compare withthose of SARS-CoV-2. There is also a need to understand the vulnerability and response toCOVID-19 of the NHS workforce of healthcare workers (HCWs). HCW present a cohort withlikely higher exposure and seroconversion rates than the general population, but who canbe followed up with potential for serial testing enabling an insight into early diseaseand markers of risk for disease severity. We have set up "COVID-19: Healthcare workerBioresource: Immune Protection and Pathogenesis in SARS-CoV-2". This urgent fieldworkaims to secure significant (n=400) sampling of healthcare workers (demographics, swabs,blood sampling) at baseline, and weekly whilst they are well and attending work, withacute sampling (if hospitalised, via ISARIC, if their admission hospital is part of theISARIC network) and convalescent samples post illness. These will be used to addressspecific questions around the impact of baseline immune function, the earliest immuneresponses to infection, and the biology of those who get non-hospitalized disease forlocal research and as a national resource. The proposal links directly with other ongoingISARIC and community COVID projects sampling in children and the older age population.Reasonable estimates suggest the usable window for baseline sampling of NHS HCW isclosing fast (e.g. baseline sampling within 3 weeks).
Unity Health Toronto
COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposureprophylaxis (PEP) against on COVID-19 was identified as an urgent research priority bythe WHO, and lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19treatment and PEP, with a good safety profile and global availability. This is a clusterrandomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that willaddress the immediate need for preventive interventions, generate key data on COVID-19transmission, and serve as a research platform for future vaccines and preventive agents.